We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-4.22%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$740M
AUM Growth
+$30.5M
Cap. Flow
-$239M
Cap. Flow %
-32.31%
Top 10 Hldgs %
67%
Holding
218
New
56
Increased
59
Reduced
50
Closed
36

Top Buys

Rank Stock Value
1
BTBT icon
Bit Digital
BTBT
+$40.7M
2
SLAI
SOLAI Ltd ADS
SLAI
+$15.2M
3
VRPX
Virpax Pharmaceuticals, Inc. Common Stock
VRPX
+$7.02M
4
FLUX icon
Flux Power
FLUX
+$6.05M
5
VXX icon
iPath Series B S&P 500 VIX Short-Term Futures ETN
VXX
+$5.87M

Top Sells

Rank Stock Value
1
LNAI
Lunai Bioworks
LNAI
+$7.71M
2
ATOS icon
Atossa Therapeutics
ATOS
+$4.06M
3
ATER icon
Aterian
ATER
+$4M
4
ASXC
Asensus Surgical, Inc.
ASXC
+$2.95M
5
RDHL
Redhill Biopharma
RDHL
+$2.34M

Sector Composition

Rank Sector Weight
1 Healthcare 6.89%
2 Financials 5.45%
3 Technology 3.65%
4 Industrials 1.84%
5 Communication Services 0.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GYRE icon
126
CALL
Gyre Therapeutics
GYRE
$668M
$350K 0.05%
+114
New +$3.75K
PRFX icon
127
PRF Technologies Ltd
PRFX
$3.25M
$326K 0.04%
98
-192
-66% -$670K
SBEV.WS
128
DELISTED
Splash Beverage Group, Inc. Warrants to purchase 1/40th of a share of Common Stock at an exercise price of $184.00
SBEV.WS
$321K 0.04%
605,659
-254,950
-30% -$231K
RCON icon
129
PUT
Recon Technology
RCON
$39.6M
$319K 0.04%
+63
New +$3.65K
VEEE icon
130
Twin Vee PowerCats
VEEE
$8.51M
$319K 0.04%
+240
New +$392K
NCTY
131
CALL
The9 Ltd
NCTY
$70.6M
$297K 0.04%
29
-13
-31% -$1.64K
DMK
132
PUT
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$293K 0.04%
+43
New +$3.15K
PHIO icon
133
PUT
Phio Pharmaceuticals
PHIO
$11.7M
$281K 0.04%
13
-2
-13% -$418
QTEX
134
QTREX Quantum
QTEX
$48.6M
$275K 0.04%
+102,553
New +$377K
AUTL
135
CALL
Autolus Therapeutics
AUTL
$386M
$268K 0.04%
+409
New +$2.58K
UK icon
136
Ucommune International Ltd Class A Ordinary Shares
UK
$1.32M
$260K 0.04%
124
+82
+195% +$258K
INFI
137
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$241K 0.03%
70,431
-371,042
-84% -$1.14M
ATNM icon
138
Actinium Pharmaceuticals
ATNM
$27.2M
$235K 0.03%
+26,488
New +$184K
ADOM
139
DELISTED
ADOMANI Inc
ADOM
$232K 0.03%
850,000
-5,316,711
-86% -$1.45M
TRIL
140
CALL
DELISTED
Trillium Therapeutics Inc.
TRIL
$211K 0.03%
120
-1
-0.8% -$12
DMK
141
CALL
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$210K 0.03%
+31
New +$2.27K
ADTX
142
DELISTED
ADITXT INC
ADTX
– –
0
– –
QTEXW
143
DELISTED
QTREX Quantum Warrant
QTEXW
$208K 0.03%
+253,063
New +$249K
HMCOW
144
DELISTED
HumanCo Acquisition Corp. Warrant
HMCOW
$198K 0.03%
200,314
– –
PLUR icon
145
PUT
Pluri
PLUR
$18.1M
$197K 0.03%
93
+27
+41% +$691
SRGA
146
PUT
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$193K 0.03%
+59
New +$2.16K
ATNM icon
147
CALL
Actinium Pharmaceuticals
ATNM
$27.2M
$182K 0.02%
+205
New +$1.43K
ABVC icon
148
ABVC BioPharma
ABVC
$27.6M
$165K 0.02%
+7,156
New +$203K
NOVN
149
DELISTED
Novan, Inc. Common Stock
NOVN
$156K 0.02%
19,132
– –
ATHX
150
DELISTED
Athersys, Inc. Common Stock
ATHX
$155K 0.02%
4,658
-9,158
-66% -$348K
4 5
6
7 8

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q3 2021 Portfolio in Review

As of Q3 2021, Sabby Management held 218 positions worth $740M, up 4.3% from $709M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Sabby Management withdrew a net $239M in Q3 2021, closing 36 positions and reducing 50 holdings. Its most notable exit was Atossa Therapeutics, an estimated $4.06M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 6.9% of assets, down from 10% a quarter earlier, followed by Financials and Technology.

Against the trend, Sabby Management opened a new position in Bit Digital worth $30.5M.

  • Sabby Management's largest Q3 2021 buy was Bit Digital: 4,216,310 shares worth $30.5M.
  • Sabby Management added most to Virpax Pharmaceuticals, Inc. Common Stock in Q3 2021, an estimated $7.02M increase.
  • Sabby Management's biggest Q3 2021 reduction was Lunai Bioworks, cutting an estimated $7.71M.
  • Sabby Management fully exited Atossa Therapeutics in Q3 2021, selling an estimated $4.06M.
  • Sabby Management's ten largest holdings make up 67% of its $740M portfolio in Q3 2021.
  • Sabby Management opened 56 new positions and closed 36 in Q3 2021.
  • Sabby Management's portfolio value rose 4.3% quarter-over-quarter to $740M.

Based on Sabby Management's 13F filing for Q3 2021, filed 15 Nov 2021.